Anti-CEACAM6 antibodies and uses thereof

US10584167B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Jörg Willuda · Berlin, DE
• Mark Trautwein · Whippany, US
• Uwe Gritzan · Cologne, DE
• Christoph Freiberg · Wuppertal, DE
• Frank Dittmer · Goldkronach, DE
• Dorian Schönfeld · Cologne, DE
• Julian Marius Glück · Meerbusch, DE
• Jessica Pinkert · Wuppertal, DE
• Eva Gutierrez · Illertissen, DE
• Sven Golfier · Berlin, DE
• Simon Holton · Berlin, DE
• Philip Beckhove · Heidelberg, DE
• Yingzi Ge · Wiesloch, DE

Key dates

• Filing date: Mar 21, 2016
• Grant date: Mar 10, 2020
• Expiry date: May 24, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.